Combating inconsistent evaluation of intra-tumor immune status by a novel transcriptomic signature in hepatocellular carcinoma  

作　　者：Linmeng Zhang Ning Tang Chen Yang Haigang Geng Hualian Hang Wenxin Qin Cun Wang 

机构地区：[1]State Key Laboratory of Oncogenes and Related Genes,Shanghai Cancer Institute,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,China [2]Department of Gastrointestinal Surgery,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China [3]Department of Liver Surgery,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第3期895-897,共3页信号转导与靶向治疗（英文）

基　　金：This work was supported by the National Natural Science Foundation of China(81920108025,81874229,82072633,and 82122047);the Innovative Research Team of High-level Local Universities in Shanghai(SHSMU-ZLCX20211602);Shanghai Natural Science Foundation(22ZR1480900).

摘　　要：Dear Editor,Harnessing the power of the immune system via immune checkpoint inhibition has revolutionized the treatment paradigm of many malignancies,including hepatocellular carcinoma(HCC).1 Despite encouraging efficacy seen with the immune checkpoint blockade(ICB)agents in a subset of patients with HCC,however,there remain a large number of HCC patients experience ICB resistance and failed to derive durable benefit from these agents.

关 键 词：HEPATOCELLULAR SIGNATURE inconsistent 

分 类 号：R735.7[医药卫生—肿瘤]